PVX-410

Phase 1Biologic

MMassachusetts General Hospital

PVX-410 is one of 43 biologic programs targeting Lenalidomide. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LenalidomideActive, not recruiting

Breast CancerActive, not recruiting

LenalidomidePhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

PVX-410

MMassachusetts General Hospital

Phase 1

2 3

Tianeptine

Pfizer

Preclinical

1 4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 6

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 7

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 8

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Ibrance

Pfizer

Preclinical

1 10

Maxigesic

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Breast Cancer

NCT02826434

Q4 2027

Phase 1Active, not recruiting

Breast Cancer

NCT03362060

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT02826434·22 enrolled

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT03362060·20 enrolled

Multiple Myeloma1 trial

Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

Completed·OOncoPep, Inc.·Phase 1·NCT01718899·22 enrolled

Lenalidomide1 trial

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT02886065·19 enrolled

Triple-Negative Breast Cancer1 trial

Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

Unknown status·OOncoPep, Inc.·Phase 2·NCT04634747·53 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PVX-410. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PVX-410 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PVX-410. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: MMassachusetts General Hospital

PVX-410

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Breast Cancer2 trials

Multiple Myeloma1 trial

Lenalidomide1 trial

Triple-Negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News